Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease
for Hematopoietic and Lymphoid Cell Neoplasm
Drug: Ruxolitinib
1 location in Houston
Sponsor: M.D. Anderson Cancer Center
Sex: All·Age: 12 - 80
Code: NCT04744116·EARLY_Phase 1·Recruiting·Listed Feb 2021